High-dose metformin Review article
Article Sidebar
Published:
Jun 30, 2019
Keywords:
metformin, type 2 diabetes, adverse events, high dosage
Main Article Content
Abstract
Metformin is a first-line drug in type 2 diabetes and in the glucose abnormalities secondary to endocrine diseases such as Cushing’s syndrome. The effect on lowering of glucose levels depends on the dose of metformin. High doses of metformin has been proven safe, but many patients are still treated suboptimal because of doctors’ fears of a risk of side effects.
Article Details
How to Cite
Dzida , G., Witek , P., & Rudnicka-Drożak , E. (2019). High-dose metformin. Medycyna Faktow (J EBM), 12(2(43), 156-160. https://doi.org/10.24292/01.MF.0219.11
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. 2019 Guidelines on the management of diabetic patients. A position of Diabetes Poland. Clinical Diabetology 2019; 8(1): 1-95. DOI: 10.5603/ DK.2019.0001.
2. UK Prospective Diabetes Study (UKPDS) Group: Effects of intensive blood glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
3. Grant P.J.: The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes. Diabetes Care 1996; 19: 64-66.
4. Hirst J.A., Farmer A.J., Ali R. et al.: Quantifying the effect of metformin treatment and dose on glycemic control. Diabetes Care 2012; 35(2): 446-454. DOI: 10.2337/dc11-1465.
5. Lord J.M., Flight I.H.K., Norman R.J.: Insulin-sensitizing drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst. Rev. 2003; 3.
6. Colao A., De Block C., Gaztambide M.S. et al.: Managing hyperglycemia in patients with Cushing’s disease treated with pasireotide: medical expert recommendations. Pituitary 2014; 17(2): 180-186. DOI: 10.1007/s11102-013-0483-3.
7. Munir A., Newell-Price J.: Management of Diabetes Mellitus in Cushing`s Disease. Neuroendocrinology 2010; 92(supl. 1): 82-85. DOI: 10.1159/000314316.
8. Colao A., Petersenn S., Newell-Price J. et al.: A 12-month phase 3 study of pasireotide in Cushing’s disease. N. Engl. J. Med. 2012; 366(10): 914-924. DOI: 10.1056/NEJMoa1105743.
9. Gadelha M.R., Bronstein M.D., Brue T. et al.: Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2014; 2(11): 875-884. DOI: 10.1016/S2213-8587(14)70169-X.
10. Zdrojewicz Z., Belowska-Bień K.: Metformina – nowe spojrzenie na stary lek. Family Medicine & Primary Care Review 2013; 15: 43-45.
11. Kargulewicz A., Bogdański P., Swora-Cwynar E. et al: Pozaglikemiczne efekty metforminy. Farmacja Współczesna 2013; 6: 1-5.
12. Kujawska-Łuczak M., Pupek-Musialik D.: Metformina – efektywny lek przeciwcukrzycowy. Czy potrafimy wykorzystać jej potencjał. Forum Zaburzeń Metabolicznych 2010; 1(2): 73-82.
13. Kanto K., Ito H., Noso S. et al.: Effects of dosage and dosing frequency on the efficacy and safety of high-dose metformin in Japanese patients with type 2 diabetes mellitus. J. Diabetes Investig. 2017. DOI: 10.1111/jdi.12755.
2. UK Prospective Diabetes Study (UKPDS) Group: Effects of intensive blood glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
3. Grant P.J.: The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes. Diabetes Care 1996; 19: 64-66.
4. Hirst J.A., Farmer A.J., Ali R. et al.: Quantifying the effect of metformin treatment and dose on glycemic control. Diabetes Care 2012; 35(2): 446-454. DOI: 10.2337/dc11-1465.
5. Lord J.M., Flight I.H.K., Norman R.J.: Insulin-sensitizing drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst. Rev. 2003; 3.
6. Colao A., De Block C., Gaztambide M.S. et al.: Managing hyperglycemia in patients with Cushing’s disease treated with pasireotide: medical expert recommendations. Pituitary 2014; 17(2): 180-186. DOI: 10.1007/s11102-013-0483-3.
7. Munir A., Newell-Price J.: Management of Diabetes Mellitus in Cushing`s Disease. Neuroendocrinology 2010; 92(supl. 1): 82-85. DOI: 10.1159/000314316.
8. Colao A., Petersenn S., Newell-Price J. et al.: A 12-month phase 3 study of pasireotide in Cushing’s disease. N. Engl. J. Med. 2012; 366(10): 914-924. DOI: 10.1056/NEJMoa1105743.
9. Gadelha M.R., Bronstein M.D., Brue T. et al.: Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2014; 2(11): 875-884. DOI: 10.1016/S2213-8587(14)70169-X.
10. Zdrojewicz Z., Belowska-Bień K.: Metformina – nowe spojrzenie na stary lek. Family Medicine & Primary Care Review 2013; 15: 43-45.
11. Kargulewicz A., Bogdański P., Swora-Cwynar E. et al: Pozaglikemiczne efekty metforminy. Farmacja Współczesna 2013; 6: 1-5.
12. Kujawska-Łuczak M., Pupek-Musialik D.: Metformina – efektywny lek przeciwcukrzycowy. Czy potrafimy wykorzystać jej potencjał. Forum Zaburzeń Metabolicznych 2010; 1(2): 73-82.
13. Kanto K., Ito H., Noso S. et al.: Effects of dosage and dosing frequency on the efficacy and safety of high-dose metformin in Japanese patients with type 2 diabetes mellitus. J. Diabetes Investig. 2017. DOI: 10.1111/jdi.12755.